Medrego team has launched a separate consultancy unit to address the growing demand – CAR T-cell Advisory by Medrego is well qualified and experienced in the topic of CAR T-cell therapy – a type of treatment in which a patient’s T cells (a type of immune cell) are changed in the laboratory so they will bind to cancer cells and kill them.

What is CAR-T Cell Therapy?

CAR-T cell therapy is a form of immunotherapy that harnesses the power of the body’s own immune system to fight cancer. The process begins with the collection of T cells, a type of white blood cell that plays a crucial role in the immune response, from a patient’s blood. These T cells are then sent to a laboratory, where they are genetically modified to express a special type of receptor called a chimeric antigen receptor (CAR).

The CAR is designed to recognize and bind to a specific protein, called an antigen, that is found on the surface of cancer cells. This allows the modified T cells, now known as CAR-T cells, to specifically target and attack cancer cells while leaving healthy cells unharmed.

After the CAR-T cells are manufactured, they are infused back into the patient’s bloodstream through a vein. Once in the body, the CAR-T cells begin to multiply and seek out cancer cells that carry the antigen targeted by the CAR. Once the CAR-T cells bind to the cancer cells, they release toxic compounds that can kill the cancer cells.

Currently, CAR-T cell therapy is FDA-approved for the treatment of certain types of leukemia and lymphoma, including acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). However, it is also being studied in clinical trials for other types of cancer, such as solid tumors and multiple myeloma.

CAR-T cell therapy is an innovative and promising treatment option for cancer patients with a high potential in the future.

Source: cancer.gov

CAR T Cell Avisory by Medrego Consultancy and R&D Services

There are several consulting services that the Medrego team can provide in the field of ATMPs, Stem cell and Gene Therapy, and CAR-T cell therapy, some examples include:

1. Regulatory Consulting:

This service involves advising clients on the regulatory requirements and guidelines for CAR-T cell therapy development and commercialization, including FDA and other international regulatory agency submissions and approvals. Learn more.

2. Clinical Development Consulting:

This service involves advising clients on the design and implementation of clinical trials for CAR-T cell therapy, including study design, protocol development, and data analysis. Learn more.

3. Business Development Consulting:

This service involves advising clients on business strategy and market analysis for CAR-T cell therapy development and commercialization, including market research, product positioning, and pricing strategy. Learn more.

4. Intellectual Property Consulting:

This service involves advising clients on intellectual property protection and strategy, including patent filing and management, and licensing and partnerships. Learn more.

5. Manufacturing and Supply Chain Consulting:

This service involves advising clients on the development and optimization of manufacturing processes and supply chain strategies for CAR-T cell therapy production. Learn more.

6. Quality Management Consulting:

This service involves advising clients on the development and implementation of quality management systems (QMS) for CAR-T cell therapy development and manufacturing. Learn more.

Get in Touch With Us and Learn More About CAR T-Cell Consultancy

Share your needs and get a quote.

Outsource your key needs and business expert consultations to be more competitive:

cartcell@medrego.com
+44 20 8144 1888
CAR T-Cell Advisory by Medrego

Car tcell advisory by Medrego